France
# |
Name |
Net Cash Used For Investing Activities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 22.77 M
|
Dec. 31, 2023 | USD 2.01 | -0.78% |
|
France |
|
2 |
USD -97.13 K
|
Dec. 31, 2023 | USD 2.58 | -11.21% |
|
France |
|
3 |
USD -152.32 K
|
Dec. 31, 2023 | USD 5.64 | -2.27% |
|
France |
|
4 |
USD -275.94 K
|
Dec. 31, 2023 | USD 1.39 | 1.77% |
|
France |
|
5 |
USD -350.99 K
|
Dec. 31, 2023 | USD 26.53 | -0.92% |
|
France |
|
6 |
USD -385.21 K
|
Dec. 31, 2023 | USD 3.47 | -1.52% |
|
France |
|
7 |
USD -559.60 K
|
Dec. 31, 2023 | USD 6.63 | -0.22% |
|
France |
|
8 |
USD -661.39 K
|
March 31, 2024 | USD 16.83 | 1.50% |
|
France |
|
9 |
USD -677.70 K
|
Dec. 31, 2023 | USD 1.64 | 4.90% |
|
France |
|
10 |
USD -808.00 K
|
Dec. 31, 2023 | USD 4.22 | -0.94% |
|
France |
|
11 |
USD -2.21 M
|
Dec. 31, 2023 | USD 3.53 | -0.92% |
|
France |
|
12 |
USD -8.53 M
|
Dec. 31, 2023 | USD 2.43 | 0.68% |
|
France |
|
13 |
USD -8.93 M
|
Dec. 31, 2023 | USD 5.91 | -2.66% |
|
France |
|
14 |
USD -17.73 M
|
Dec. 31, 2023 | USD 0.65 | 1.19% |
|
France |
|
15 |
USD -20.84 M
|
Dec. 31, 2023 | USD 75.53 | 2.94% |
|
France |
|
16 |
USD -22.72 M
|
Dec. 31, 2023 | USD 3.21 | 17.34% |
|
France |
|
17 |
USD -6.84 B
|
Dec. 31, 2023 | USD 107.78 | 1.15% |
|
France |
The Vaccines company in France with the highest Net Cash Used For Investing Activities is Innate Pharma S.A. (Paris Stock Exchange: IPH.PA) at USD 22.77 M.
The Vaccines company in France with the lowest Net Cash Used For Investing Activities is Sanofi (Paris Stock Exchange: SAN.PA) at USD -6.84 B.
The top 10 Vaccines companies in France by Net Cash Used For Investing Activities are Innate Pharma S.A., Aelis Farma SA, Adocia SA, Valbiotis SA, Eurobio Scientific SA, Nanobiotix S.A., OSE Immunotherapeutics SA, MedinCell S.A., AB Science S.A. and DBV Technologies S.A..
The bottom 10 Vaccines companies in France by Net Cash Used For Investing Activities are Sanofi, Valneva SE, Vetoquinol SA, Novacyt S.A., ABIVAX SA, Inventiva S.A., genOway SA, DBV Technologies S.A., AB Science S.A. and MedinCell S.A..